Advertisement
Screener

Q/C Technologies, Inc. (QCLS) Overview

Q/C Technologies, Inc. (QCLS) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.79; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.19; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -2.50; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -51.10; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.42$0.74$1.31$2.32$4.11$7.272025-09-292026-09-29$0.42$3.93$36.91$346.45$3,251.92$30,523.502021-09-292026-09-29$0.42$10.50$263.31$6,601.25$165,493.58$4.15M2016-09-292026-09-29$0.42$11.55$318.28$8,772.85$241,806.04$6.66M2014-01-232026-09-29$0.42$11.55$318.28$8,772.85$241,806.04$6.66M2014-01-232026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$0.89
Previous close
$0.83
Change
$0.06
Change (%)
7.20%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

QCLS
-77.62%
S&P 500
(m)

1 year

QCLS
-78.11%
S&P 500
(m)

3 years

QCLS
-99.95%
S&P 500
(m)

5 years

QCLS
-100.00%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.79

-51.18-38.39-25.59-12.80-0.0131 Mar 2025: estimate (m); actual -0.3631 Mar 2025(m)30 Jun 2025: estimate (m); actual -51.1030 Jun 2025(m)30 Sept 2025: estimate (m); actual -2.5030 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.1931 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.7930 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.79(m)(m)
1 Jan 202631 Mar 2026(m)-0.19(m)(m)
1 Jul 202530 Sept 2025(m)-2.50(m)(m)
1 Apr 202530 Jun 2025(m)-51.10(m)(m)
1 Jan 202531 Mar 2025(m)-0.36(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -8.66

-1080.95-812.00-543.05-274.10-5.1531 Dec 2022: estimate (m); actual -11.7431 Dec 2022(m)31 Dec 2023: estimate (m); actual -5.3331 Dec 2023(m)31 Dec 2024: estimate (m); actual -1080.8731 Dec 2024(m)31 Dec 2025: estimate (m); actual -8.6631 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-8.66(m)(m)
1 Jan 202431 Dec 2024(m)-1080.87(m)(m)
1 Jan 202331 Dec 2023(m)-5.33(m)(m)
1 Jan 202231 Dec 2022(m)-11.74(m)(m)

Revenue vs. Earnings

USD

30 Jun 2020 ■ Revenue -0.00M ■ Earnings -1.09M — Profit margin 57993.06%

-1.28M-271.1%-0.64M19150.6%0.01M38572.3%0.65M57994.1%30 Jun 2019: revenue 0.46M; earnings -0.79M; profit margin -171.12%30 Jun 201930 Sept 2019: revenue 0.42M; earnings -0.84M; profit margin -198.91%30 Sept 201931 Mar 2020: revenue 0.36M; earnings -0.98M; profit margin -270.13%31 Mar 202030 Jun 2020: revenue -0.00M; earnings -1.09M; profit margin 57993.06%30 Jun 2020

31 Dec 2019 ■ Revenue 1.58M ■ Earnings -3.89M — Profit margin -246.55%

-12.55M-652.4%-6.68M-471.8%-0.81M-291.2%5.06M-110.6%31 Dec 2016: revenue 2.96M; earnings -3.30M; profit margin -111.57%31 Dec 201631 Dec 2017: revenue 3.35M; earnings -7.37M; profit margin -219.58%31 Dec 201731 Dec 2018: revenue 1.67M; earnings -10.85M; profit margin -651.37%31 Dec 201831 Dec 2019: revenue 1.58M; earnings -3.89M; profit margin -246.55%31 Dec 2019

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$0.89(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$0.89High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning QCLS

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2020.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-4.25M
Profit margin
-493.40%
Return on assets · 12 month
-34.57%
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
15.13M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
0.00%*
Total return · month
-62.00%*
Total return · quarter
-75.86%*
Total return · half year
-74.04%*
Total return · year to date
-77.62%*
Total return · 1 year
-78.11%*
Total return · 3 years
-99.95%*
Total return · 5 years
-100.00%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$862.03K
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Q/C Technologies, Inc. Overview

View more →

(m)

(m)

SEC CIK
1321834
Industry (SIC)
2835 In Vitro & In Vivo Diagnostic Substances
Country of operation
United States
Business address
1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, New York, 10036, United States
Fiscal year end
1231
Phone
856-848-8698

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
BIOMERICA INC (BMRA)United States$0.011B
VOLITIONRX LTD (VNRX)$0.003B-0.64
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92